| Literature DB >> 33521583 |
Ravindra Ganesh1, Bradley R Salonen1, M Nadir Bhuiyan1, Dennis M Bierle1, Darcie Moehnke1, Tufia C Haddad2,3, Aaron J Tande4, John Wilson1,4, Ryan T Hurt1.
Abstract
OBJECTIVE: To study the impact of a 60-day pilot of an innovative virtual-care model using general internal medicine physicians and nurses to respond rapidly to more than 1200 coronavirus disease-2019 (COVID-19)-positive nasopharyngeal polymerase chain reaction tests. PATIENTS AND METHODS: The current study was approved by the Mayo Clinic COVID-19 Research Committee and the Mayo Clinic Institutional Review Board. The data for all SARS-CoV-2-positive patients treated by our team were entered into a prospectively maintained internal research electronic data capture database. We searched this database retrospectively for the first 60 days of our program (March 23, 2020 to May 22, 2020). The data included basic deidentified demographics; symptoms at intake into the program; date of symptom onset; risk factors; location; and outcomes including hospitalization, admission to intensive care unit, and death.Entities:
Keywords: COVID-19, coronavirus disease 2019; ED, emergency department; EHR, electronic health record; GIM, general internal medicine; ICU, intensive care unit; ID, infectious diseases; OCPHD, Olmsted County Public Health Department; PCR, polymerase chain reaction; PPE, personal protective equipment; RMS, remote monitoring system; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization
Year: 2020 PMID: 33521583 PMCID: PMC7833108 DOI: 10.1016/j.mayocpiqo.2020.12.003
Source DB: PubMed Journal: Mayo Clin Proc Innov Qual Outcomes ISSN: 2542-4548
Figure 1Risk stratification for COVID patients.
Baseline Demographics
| Characteristic | N=828 |
|---|---|
| Age, median (IQR) | 40 (29, 54) |
| Gender, n (%) | |
| Female | 444 (54%) |
| Male | 384 (46%) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 162 (20%) |
| Not Hispanic or Latino | 635 (77%) |
| Other | 31 (3.7%) |
| Race, n (%) | |
| American Indian/Alaskan Native | 3 (0.4%) |
| Asian | 50 (6.0%) |
| Black or African American | 209 (25%) |
| Other | 141 (17%) |
| White | 425 (51%) |
| State, n (%) | |
| Iowa | 11 (1.3%) |
| Minnesota | 793 (96%) |
| Nebraska | 1 (0.1%) |
| New York | 1 (0.1%) |
| North Dakota | 1 (0.1%) |
| Texas | 1 (0.1%) |
| Wisconsin | 20 (2.4%) |
IQR, interquartile range.
Figure 2Risk status.
Risk Factors
| Characteristic | Female, N=444 | Male, N=384 | Overall, N=828 |
|---|---|---|---|
| Age >65 | 29 (6.5%) | 33 (8.6%) | 62 (7.5%) |
| Diabetes | 56 (13%) | 34 (8.9%) | 90 (11%) |
| COPD/emphysema | 6 (1.4%) | 5 (1.3%) | 11 (1.3%) |
| Asthma | 41 (9.2%) | 23 (6.0%) | 64 (7.7%) |
| Chronic lung disease | 16 (3.6%) | 11 (2.9%) | 27 (3.3%) |
| Congestive heart failure | 10 (2.3%) | 4 (1.0%) | 14 (1.7%) |
| Coronary artery disease | 12 (2.7%) | 14 (3.6%) | 26 (3.1%) |
| Current smoker | 21 (4.7%) | 29 (7.6%) | 50 (6.0%) |
| Active chemotherapy | 3 (0.7%) | 4 (1.0%) | 7 (0.8%) |
| Bone marrow transplant | 1 (0.2%) | 0 (0%) | 1 (0.1%) |
| Solid organ transplant | 1 (0.2%) | 2 (0.5%) | 3 (0.4%) |
| Other immune compromised condition | 9 (2.0%) | 9 (2.3%) | 18 (2.2%) |
| End-stage liver disease | 3 (0.7%) | 2 (0.5%) | 5 (0.6%) |
| Obesity | 24 (5.4%) | 7 (1.8%) | 31 (3.7%) |
| Other | 57 (13%) | 35 (9.1%) | 92 (11%) |
| None | 267 (60%) | 241 (63%) | 508 (61%) |
Statistics presented: n (%).
COPD, chronic obstructive pulmonary disease.
Symptoms by Age Group
| Characteristic | <20 (N=40) | 20-39 (N=373) | 40-59 (N=289) | 60-79 (N=111) | >80 (N=15) | Overall (N=828) |
|---|---|---|---|---|---|---|
| Dyspnea | 6 (15%) | 54 (14%) | 51 (18%) | 29 (26%) | 2 (13%) | 142 (17%) |
| Chest pain or tightness | 4 (10%) | 47 (13%) | 37 (13%) | 5 (4.5%) | 1 (6.7%) | 94 (11%) |
| Cough | 19 (48%) | 162 (43%) | 146 (51%) | 53 (48%) | 12 (80%) | 392 (47%) |
| Fever | 11 (28%) | 115 (31%) | 102 (35%) | 37 (33%) | 2 (13%) | 267 (32%) |
| Chills | 7 (18%) | 85 (23%) | 67 (23%) | 27 (24%) | 1 (6.7%) | 187 (23%) |
| Myalgia | 10 (25%) | 134 (36%) | 123 (43%) | 43 (39%) | 1 (6.7%) | 311 (38%) |
| Sore throat | 10 (25%) | 87 (23%) | 51 (18%) | 19 (17%) | 1 (6.7%) | 168 (20%) |
| Headache | 15 (38%) | 157 (42%) | 113 (39%) | 28 (25%) | 2 (13%) | 315 (38%) |
| Anosmia/dysguesia | 9 (22%) | 119 (32%) | 72 (25%) | 20 (18%) | 1 (6.7%) | 221 (27%) |
| Congestion/rhinorrhea | 11 (28%) | 118 (32%) | 61 (21%) | 25 (23%) | 4 (27%) | 219 (26%) |
| Nausea/vomiting/abdominal pain | 3 (7.5%) | 37 (9.9%) | 37 (13%) | 12 (11%) | 2 (13%) | 91 (11%) |
| Diarrhea | 7 (18%) | 49 (13%) | 46 (16%) | 21 (19%) | 4 (27%) | 127 (15%) |
| Lightheadedness and/or dizziness | 7 (18%) | 59 (16%) | 45 (16%) | 20 (18%) | 3 (20%) | 134 (16%) |
| Fatigue | 1 (2.5%) | 18 (4.8%) | 24 (8.3%) | 13 (12%) | 3 (20%) | 59 (7.1%) |
| Other | 2 (5.0%) | 25 (6.7%) | 20 (6.9%) | 13 (12%) | 2 (13%) | 62 (7.5%) |
| None | 3 (7.5%) | 47 (13%) | 35 (12%) | 15 (14%) | 1 (6.7%) | 101 (12%) |
Statistics presented: n (%).
Emergency Department Visits
| Characteristic | Admit from emergency department | Overall ED visits (N=138) | |
|---|---|---|---|
| No (N=83) | Yes (N= 55) | ||
| Age Group | |||
| <20 | 5 (6.0%) | 0 (0%) | 5 (3.6%) |
| 20-39 | 30 (36%) | 8 (15%) | 38 (28%) |
| 40-59 | 37 (45%) | 29 (53%) | 66 (48%) |
| 60-79 | 9 (11%) | 14 (25%) | 23 (17%) |
| >80 | 2 (2.4%) | 4 (7.3%) | 6 (4.3%) |
Statistics presented: n (%)
ED, emergency department.
Hospitalization and ICU Stays
| Characteristic | ICU stay | Overall hospitalizations (N=55) | Length of stay (days, IQR) | |
|---|---|---|---|---|
| No (N=35) | Yes (N=20) | |||
| Age group | ||||
| 20-39 | 7 (20%) | 1 (5.0%) | 8 (15%) | 3 (2,3) |
| 40-59 | 17 (49%) | 12 (60%) | 29 (53%) | 7 (2,11) |
| 60-79 | 7 (20%) | 7 (35%) | 14 (25%) | 11 (8,18) |
| >80 | 4 (11%) | 0 (0%) | 4 (7.3%) | 4 (2,8) |
Statistics presented: n (%).
ICU, intensive care unit; IQR, interquartile range.